Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Taysha Gene Therapies, Inc. (TSHA)

0.68   -0.02 (-2.84%) 03-24 16:00
Open: 0.683 Pre. Close: 0.6999
High: 0.756 Low: 0.65
Volume: 559,429 Market Cap: 42(M)

Technical analysis

as of: 2023-03-24 4:30:41 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.12     One year: 1.34
Support: Support1: 0.64    Support2: 0.54
Resistance: Resistance1: 0.95    Resistance2: 1.14
Pivot: 0.85
Moving Average: MA(5): 0.71     MA(20): 0.89
MA(100): 1.68     MA(250): 2.79
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 7.7     %D(3): 10.1
RSI: RSI(14): 25.3
52-week: High: 7.07  Low: 0.64
Average Vol(K): 3-Month: 532 (K)  10-Days: 388 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TSHA ] has closed above bottom band by 17.0%. Bollinger Bands are 20.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.76 - 0.76 0.76 - 0.77
Low: 0.64 - 0.65 0.65 - 0.65
Close: 0.67 - 0.68 0.68 - 0.69

Company Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Headline News

Thu, 23 Mar 2023
DelveInsight Highlights Major Advances, Transformative Therapies ... - Medgadget

Wed, 15 Mar 2023
Taysha Gene Therapies to Release Fourth Quarter and Full-Year ... - GlobeNewswire

Thu, 09 Feb 2023
Fmr Cuts Stake in Taysha Gene Therapies (TSHA) - Nasdaq

Wed, 01 Feb 2023
Premarket Mover: Taysha Gene Therapies Inc (TSHA) Down 21.95% - InvestorsObserver

Tue, 31 Jan 2023
Taysha Gene Therapies Provides Update on TSHA-120 Program in ... - GlobeNewswire

Mon, 19 Dec 2022
Taysha Gene Therapies names new CEO (NASDAQ:TSHA) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 62 (M)
Shares Float 37 (M)
% Held by Insiders 39.8 (%)
% Held by Institutions 24 (%)
Shares Short 1,720 (K)
Shares Short P.Month 926 (K)

Stock Financials

EPS -3.81
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.65
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -54.8
Return on Equity (ttm) -212.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.46
Qtrly Earnings Growth 0
Operating Cash Flow -143 (M)
Levered Free Cash Flow -120 (M)

Stock Valuations

PE Ratio -0.18
PEG Ratio 0
Price to Book value 0.18
Price to Sales 0
Price to Cash Flow -0.3

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.